CASSIOPE: A prospective noninterventional study of cabozantinib treatment following prior vascular endothelial growth factor (VEGF) -targeted therapy in patients with advanced renal cell carcinoma (aRCC).

被引：0
|
作者：
Staehler, Michael D.
Bigot, Pierre
Barthelemy, Philippe
Hamberg, Paul
Suarez, Cristina
Eymard, Jean-Christophe
Gajate, Pablo
Perrot, Valerie
Qvick, Bryan
Dutailly, Pascale
Procopio, Giuseppe
机构：
[1] Univ Munich, Munich, Germany
[2] Ctr Hosp Univ Angers, Angers, France
[3] Inst Cancerol Strasbourg Europe, Strasbourg, France
[4] Franciscus Gasthuis & Vlietland, Dept Med Oncol, Rotterdam, Netherlands
[5] Vall dHebron Univ Hosp, Barcelona, Spain
[6] Univ Autonoma Barcelona, Inst Oncol, Barcelona, Spain
[7] Inst Jean Godinot, Reims, France
[8] Hosp Univ Ramon y Cajal, Madrid, Spain
[9] Ipsen Pharma, Boulogne, France
[10] Ipsen, Paris, France
[11] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4529
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Cabozantinib in adult patients with advanced renal cell carcinoma following prior systemic checkpoint inhibition therapy: a retrospective, non-interventional study
    Gruenwald, Viktor
    Boegemann, Martin
    Rafyian, Reza
    Niegisch, Guenter
    Schnabel, Marco
    Floercken, Anne
    Maasberg, Michael
    Maintz, Christoph
    Zahn, M. -O.
    Wortmann, Anke
    Hinkel, Andreas
    Casper, Jochen
    Darr, Christopher
    Hilser, Thomas
    Schulze, Matthias
    Sookthai, Disorn
    Schonherr, Caroline
    Ivanyi, Philipp
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 98 - 98
  • [32] THE COMPARATIVE COST-EFFECTIVENESS OF CABOZANTINIB, EVEROLIMUS AND AXITINIB IN ADVANCED RENAL CELL CARCINOMA (ARCC) AFTER FAILURE OF PRIOR THERAPY: SCOTTISH PERSPECTIVE
    Lister, J.
    Vataire, A.
    Amzal, B.
    Dinet, J.
    Meng, J.
    Karcher, H.
    Gabriel, S.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A440 - A440
  • [33] Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma Feasibility and Clinical Outcome
    Sadeghi, Sarmad
    Albiges, Laurence
    Wood, Laura S.
    Black, Shari L.
    Gilligan, Timothy D.
    Dreicer, Robert
    Garcia, Jorge A.
    Escudier, Bernard J.
    Rini, Brian I.
    [J]. CANCER, 2012, 118 (13) : 3277 - 3282
  • [34] The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy
    Choueiri, Toni K.
    Xie, Wanling
    Kollmannsberger, Christian
    North, Scott
    Knox, Jennifer J.
    Lampard, J. Geoffrey
    McDermott, David F.
    Rini, Brian I.
    Heng, Daniel Y. C.
    [J]. JOURNAL OF UROLOGY, 2011, 185 (01): : 60 - 66
  • [35] Tubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor (VEGF) in renal cell carcinoma
    Nakagawa, M
    Emoto, A
    Hanada, T
    Nasu, N
    Nomura, Y
    [J]. BRITISH JOURNAL OF UROLOGY, 1997, 79 (05): : 681 - 687
  • [36] Final Analysis of a Noninterventional Study on Cabozantinib in Patients With Advanced Renal Cell Carcinoma After Prior Checkpoint Inhibitor Therapy of the German Interdisciplinary Working Group on Renal Tumors (IAG-N)
    Viktor, Gruenwald
    Martin, Bogemann
    Mohammad-Reza, Rafiyan
    Guenter, Niegisch
    Marco, Schnabel
    Anne, Florcken
    Michael, Maasberg
    Christoph, Maintz
    Mark-Oliver, Zahn
    Anke, Wortmann
    Andreas, Hinkel
    Jochen, Casper
    Darr, C.
    Thomas, Hilser
    Schulze, M.
    Disorn, Sookthai
    Philipp, Ivanyi
    [J]. CLINICAL GENITOURINARY CANCER, 2024, 22 (05)
  • [37] An exploratory study of radium-223 and vascular endothelial growth factor targeted therapy (VEGF TT) in patients (pts) with metastatic renal cell carcinoma (mRCC) and bone metastases (BM).
    McKay, Rana R.
    Gray, Kathryn P.
    Polacek, Laura
    Pomerantz, Mark M.
    Krajewski, Katherine M.
    Jacene, Heather
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [38] Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: Current status and future directions
    Rini, Brian I.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (04) : 1098 - 1106
  • [39] Reconciling the Role of Vascular Endothelial Growth Factor-Targeted Therapies in Adjuvant Renal Cell Carcinoma Treatment
    Kim, Won
    Parikh, Mamta
    Ryan, Christopher
    Lara, Primo
    [J]. KIDNEY CANCER, 2018, 2 (02) : 95 - 102
  • [40] Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Adult Metastatic Xp11.2 Translocation Renal Cell Carcinoma
    Choueiri, Toni K.
    Lim, Zita Dubauskas
    Hirsch, Michelle S.
    Tamboli, Pheroze
    Jonasch, Eric
    McDermott, David F.
    Dal Cin, Paola
    Corn, Paul
    Vaishampayan, Ulka
    Heng, Daniel Y. C.
    Tannir, Nizar M.
    [J]. CANCER, 2010, 116 (22) : 5219 - 5225
12345